264
Participants
Start Date
April 18, 2022
Primary Completion Date
July 12, 2024
Study Completion Date
August 6, 2024
Depemokimab (GSK3511294)
Depemokimab (GSK3511294) was administered using a pre-filled syringe.
Placebo
Placebo was administered as normal saline using a pre-filled syringe.
GSK Investigational Site, Jerez de la Frontera
GSK Investigational Site, Rozzano MI
GSK Investigational Site, Milan
GSK Investigational Site, Varese
GSK Investigational Site, Baltimore
GSK Investigational Site, Norfolk
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Pamplona
GSK Investigational Site, Hialeah
GSK Investigational Site, CapaIstanbul
GSK Investigational Site, Padua
GSK Investigational Site, Izmir
GSK Investigational Site, Santander
GSK Investigational Site, Bologna
GSK Investigational Site, Seville
GSK Investigational Site, Valladolid
GSK Investigational Site, Zaragoza
GSK Investigational Site, Grand Rapids
GSK Investigational Site, Tekirdağ
GSK Investigational Site, Columbia
GSK Investigational Site, Oklahoma City
GSK Investigational Site, McKinney
GSK Investigational Site, Fort Worth
GSK Investigational Site, San Antonio
GSK Investigational Site, McAllen
GSK Investigational Site, Napoli
GSK Investigational Site, Tucson
GSK Investigational Site, Catania
GSK Investigational Site, Roseville
GSK Investigational Site, Shanghai
GSK Investigational Site, Shanghai
GSK Investigational Site, Nanjing
GSK Investigational Site, Zibo Shandong Province
GSK Investigational Site, Timișoara
GSK Investigational Site, Hangzhou
GSK Investigational Site, Xiamen
GSK Investigational Site, Cluj-Napoca
GSK Investigational Site, Changsha
GSK Investigational Site, Wuhan
GSK Investigational Site, Brasov
GSK Investigational Site, Brasov
GSK Investigational Site, Guangzhou
GSK Investigational Site, Zhongshan
GSK Investigational Site, Chengdu
GSK Investigational Site, Gothenburg
GSK Investigational Site, Lund
GSK Investigational Site, Stockholm
GSK Investigational Site, Stockholm
GSK Investigational Site, Ankara
GSK Investigational Site, New Haven
GSK Investigational Site, Morgantown
GSK Investigational Site, Suzhou
GSK Investigational Site, Pisa
GSK Investigational Site, Roma
GSK Investigational Site, Roma
GSK Investigational Site, Aichi
GSK Investigational Site, Chiba
GSK Investigational Site, Chiba
GSK Investigational Site, Gunma
GSK Investigational Site, Hyōgo
GSK Investigational Site, Hyōgo
GSK Investigational Site, Ibaraki
GSK Investigational Site, Kanagawa
GSK Investigational Site, Nagano
GSK Investigational Site, Shiga
GSK Investigational Site, Shizuoka
GSK Investigational Site, Tokyo
GSK Investigational Site, ?Od?
GSK Investigational Site, Gdansk
GSK Investigational Site, Katowice
GSK Investigational Site, Krakow
GSK Investigational Site, Krakow
GSK Investigational Site, Lubin
GSK Investigational Site, Nadarzyn
GSK Investigational Site, Poznan
GSK Investigational Site, Strzelce Opolskie
GSK Investigational Site, Bucharest
GSK Investigational Site, Bucharest
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
Lead Sponsor
GlaxoSmithKline
INDUSTRY